Table 3 Multivariate analysis including all patients (n = 44,498)
Hazard Ratio | 95% Confidence Interval | p-value | ||
|---|---|---|---|---|
Sex | Male | 1.00 | Ref | < 0.0001 |
Female | 0.82 | 0.80–0.84 | ||
Age | 18–59 | 1.00 | Ref | < 0.0001 |
60–69 | 1.02 | .099–1.05 | ||
70–79 | 1.05 | 1.02–1.08 | ||
80+ | 1.15 | 1.10–1.20 | ||
Comorbidity | 0 | 1.00 | Ref | < 0.0001 |
1 | 1.08 | 1.05–1.10 | ||
> 2 | 1.23 | 1.19–1.28 | ||
Histology | Adenocarcinoma | 1.00 | Ref | < 0.0001 |
Non-adenocarcinoma | 1.14 | 1.12–1.16 | ||
Race | White | 1.00 | Ref | < 0.0001 |
Non-white | 0.88 | 0.85–0.91 | ||
Insurance | Uninsured | 1.00 | Ref | 0.012 |
Insured | 0.92 | 0.88–0.98 | ||
Facility Type | Academic | 1.00 | Ref | < 0.0001 |
Nonacademic | 1.16 | 1.13–1.18 | ||
Systemic Therapy | Chemotherapy | 1.00 | Ref | < 0.0001 |
Immunotherapy | 0.81 | 0.78–0.84 | ||
Radiation | No Radiation | 1.00 | Ref | < 0.0001 |
EBRT | 1.16 | 1.13–1.18 | ||
SRT | 0.73 | 0.69–0.78 | ||